Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | R248Q |
Impact List | missense |
Protein Effect | loss of function |
Gene Variant Descriptions | TP53 R248Q is a hotspot mutation that lies within the DNA-binding domain of the Tp53 protein (PMID: 22713868). R248Q results in increased proliferation, migration, invasion, and protein stability and altered subcellular localization in culture (PMID: 37030635), loss of DNA binding and decreased transactivation of Tp53 targets and interference with wild-type Tp53 transactivation, leads to resistance to apoptosis and failure of G1 arrest in cell culture (PMID: 23538418, PMID: 16861262, PMID: 31395785), as well as increased Akt activation, Stat3 dependent migration, and enhanced tumor onset and growth in mouse models (PMID: 30107178). |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon7 TP53 R248Q TP53 mutant TP53 inact mut TP53 R248Q |
Transcript | NM_000546.6 |
gDNA | chr17:g.7674220C>T |
cDNA | c.743G>A |
Protein | p.R248Q |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_000546 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001126114.2 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001126112.2 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001126113 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001407268.1 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001126113.3 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001407264.1 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001126114.3 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001126112.3 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001126114 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001126112 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
NM_001407270.1 | chr17:g.7674220C>T | c.743G>A | p.R248Q | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|